Who is sponsoring NCT06902051?

NCT06902051 is sponsored by Nanfang Hospital, Southern Medical University.

What drugs are being tested in NCT06902051?

Interventions in NCT06902051: Lateral Decubitus position, Lateral Decubitus device.

What condition does NCT06902051 study?

NCT06902051 studies Breast Cancer Early Stage Breast Cancer (Stage 1-3).

Is NCT06902051 still recruiting?

NCT06902051 is currently recruiting now. Last updated 11 May 2025.

Last reviewed 2025-05-11 · How we verify

NCT06902051: LDPLBC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study on the Use of Lateral Decubitus Position in Left Breast Cancer Patients Undergoing Adjuvant Radiotherapy

Recruiting now NA Last updated 11 May 2025

What this trial tests

NA trial testing Lateral Decubitus position in Breast Cancer Early Stage Breast Cancer (Stage 1-3) in 86 participants. Currently enrolling.

Timeline

14 April 2025

Primary endpoint
30 April 2028

31 May 2028

Quick facts

Lead sponsor	Nanfang Hospital, Southern Medical University
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	86
Start date	14 April 2025
Primary completion	30 April 2028
Estimated completion	31 May 2028
Sites	2 locations across China

Drugs / interventions tested

Lateral Decubitus position
Lateral Decubitus device

Conditions studied

Breast Cancer Early Stage Breast Cancer (Stage 1-3) — all drugs for Breast Cancer Early Stage Breast Cancer (Stage 1-3) →

Sponsor

Nanfang Hospital, Southern Medical University

Who can join

Adults 18 to 70, female only, with Breast Cancer Early Stage Breast Cancer (Stage 1-3). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A Prospective Study on the Application of Lateral Decubitus Position in Patients with Left Breast Cancer Undergoing Adjuvant Radiotherapy

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Breast Cancer Early Stage Breast Cancer (Stage 1-3)

Currently open trials in the same condition.

NCT07331506 — Validation of the Oncoliq Test for the Early Detection of Breast Cancer. · recruiting
NCT06781996 — A Study to Determine the Efficacy of a Digital Self-management Support Tool to Improve the Quality of Life During Adjuva · Phase 3 · recruiting
NCT06970912 — ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer · Phase 2 · recruiting
NCT07206394 — Feasibility Trial of ScarWork for Post-breast Surgery Pain Syndrome. · NA · recruiting
NCT06995118 — The Application of "HUAXI Hole 1" in Reverse-sequence Endoscopic Nipple-sparing Mastectomy With Direct-to-implant Breast · NA · recruiting

Other Nanfang Hospital, Southern Medical University trials

Trials by the same sponsor.

NCT07091994 — A Trial of Edaravone Dexborneol in Acute Ischemic Stroke With Active Malignancy · Phase 4 · not yet recruiting
NCT06444022 — hAESCs Prevent Acute Graft-versus-host Disease After Hematopoietic Stem Cell Transplantation · Phase 1 · withdrawn
NCT07537777 — Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted T · Phase 2 · not yet recruiting
NCT07481032 — Effect of Fufang Biejiaruangan Combined With Antiviral Therapy on the Incidence of Hepatocellular Carcinoma in Patients · NA · not yet recruiting
NCT07511894 — Beta-Blockers on the Efficacy of Neoadjuvant Immunotherapy for Gastric Cancer · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06902051 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nanfang Hospital, Southern Medical University
Last refreshed: 11 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06902051.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing